These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34082257)

  • 1. Playing hide and seek: Tumor cells in control of MHC class I antigen presentation.
    Jongsma MLM; Neefjes J; Spaapen RM
    Mol Immunol; 2021 Aug; 136():36-44. PubMed ID: 34082257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide Channeling: The Key to MHC Class I Immunosurveillance?
    Yewdell JW; Dersh D; Fåhraeus R
    Trends Cell Biol; 2019 Dec; 29(12):929-939. PubMed ID: 31662235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
    Humphreys RE; Hillman GG; von Hofe E; Xu M
    Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MHC class I antigens, immune surveillance, and tumor immune escape.
    Garcia-Lora A; Algarra I; Garrido F
    J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC class I antigens and immune surveillance in transformed cells.
    Aptsiauri N; Cabrera T; Garcia-Lora A; Lopez-Nevot MA; Ruiz-Cabello F; Garrido F
    Int Rev Cytol; 2007; 256():139-89. PubMed ID: 17241907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
    Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
    Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class I MHC presentation of exogenous antigens.
    Harding CV
    J Clin Immunol; 1996 Mar; 16(2):90-6. PubMed ID: 8690777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-examining class-I presentation and the DRiP hypothesis.
    Rock KL; Farfán-Arribas DJ; Colbert JD; Goldberg AL
    Trends Immunol; 2014 Apr; 35(4):144-52. PubMed ID: 24566257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts.
    Sundstrom JB; Ansari AA
    Transpl Immunol; 1995 Dec; 3(4):273-89. PubMed ID: 8665146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells.
    Mangino G; Grazia Capri M; Barnaba V; Alberti S
    Int J Cancer; 2002 Oct; 101(4):353-9. PubMed ID: 12209960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-presentation: underlying mechanisms and role in immune surveillance.
    Rock KL; Shen L
    Immunol Rev; 2005 Oct; 207():166-83. PubMed ID: 16181335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative processing pathways for MHC class I-restricted epitope presentation to CD8+ cytotoxic T lymphocytes.
    Reimann J; Böhm W; Schirmbeck R
    Biol Chem Hoppe Seyler; 1994 Nov; 375(11):731-6. PubMed ID: 7535058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of immunological synapse by membrane-bound and soluble ligands.
    González PA; Carreño LJ; Figueroa CA; Kalergis AM
    Cytokine Growth Factor Rev; 2007; 18(1-2):19-31. PubMed ID: 17344089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of cellular immune responses to antigenic tumor peptides.
    Pietersz GA; Apostolopoulos V; McKenzie IF
    Cell Mol Life Sci; 2000 Feb; 57(2):290-310. PubMed ID: 10766024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of the antigen presenting cell in rat autoimmune myocarditis: evidence of bone marrow derivation and non-requirement for MHC class I compatibility with pathogenic T cells.
    Ratcliffe NR; Wegmann KW; Zhao RW; Hickey WF
    J Autoimmun; 2000 Nov; 15(3):369-79. PubMed ID: 11040077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Processing of MHC class I presented antigens].
    van Endert P
    Med Sci (Paris); 2006; 22(8-9):727-32. PubMed ID: 16962047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection.
    Mazzaccaro RJ; Gedde M; Jensen ER; van Santen HM; Ploegh HL; Rock KL; Bloom BR
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11786-91. PubMed ID: 8876215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of mRNA translation in direct MHC class I antigen presentation.
    Apcher S; Manoury B; Fåhraeus R
    Curr Opin Immunol; 2012 Feb; 24(1):71-6. PubMed ID: 22341517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
    Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
    Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.